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Abstract Tau protein levels in cerebrospinal fluid (CSF) and serum are 
elevated in patients with various central nervous system diseases. We investigated 
whether serum tau protein levels are useful for predicting and assessing disease 
activity of acute encephalopathy (AE) in enterohemorrhagic Escherichia coli (EHEC) 
O111-induced hemolytic uremic syndrome (HUS; EHEC encephalopathy). Serum 
samples were obtained from 14 patients with EHEC O111/HUS, 20 patients with 
non-EHEC-related AE, and 20 age- and sex-matched healthy controls. CSF samples 
were obtained from 2 patients with EHEC encephalopathy and 20 patients with 
non-EHEC-related AE. Tau protein levels and levels of several proinflammatory 
cytokines were quantified by enzyme-linked immunosorbent assays. Results were 
compared with the clinical features of EHEC encephalopathy, including magnetic 
resonance image (MRI) findings. Serum tau levels in patients with EHEC 
encephalopathy were significantly elevated compared with those in patients with 
EHEC O111/HUS without encephalopathy, patients with non-EHEC-related AE, and 
healthy controls. The ratio of CSF tau levels to serum tau levels was >1.0 in all 
patients with non-EHEC-related AE but <1.0 in 2 patients with EHEC encephalopathy. 
Serum tau protein levels increased rapidly and markedly in patients with severe 
EHEC 0111/HUS and encephalopathy when HUS occurred, but were not elevated in 
mild patients, even in the HUS phase. Furthermore, changes in serum tau protein 
levels in patients with EHEC encephalopathy were consistent with abnormalities on 
brain MRI and were positively correlated with proinflammatory cytokine levels. Our 
results indicate that serum tau protein might be useful to predict and assess disease 
activity of EHEC encephalopathy. 
 





Hemolytic uremic syndrome (HUS) is a multisystem disease characterized by the 
triad of microangiopathic hemolytic anemia, thrombocytopenia, and renal failure. HUS 
occurs after a prodrome of hemorrhagic colitis caused by Shiga toxin-producing 
Escherichia coli, also known as enterohemorrhagic E. coli (EHEC). Neurologic 
complications involving the central nervous system (CNS) occur in approximately 
20% of patients with HUS [1]. Common clinical symptoms include seizures and 
alteration of consciousness, and morbidity and mortality are increased in affected 
patients [2]. The pathogenesis of CNS involvement remains unclear, although various 
proinflammatory cytokines have been implicated in the pathogenesis of neurological 
complications in HUS [3, 4]. 
The most prevalent serotype involved in HUS is EHEC O157. However, EHEC 
O111 can also cause HUS and neurological complications [5, 6]. An outbreak of 
EHEC O111 occurred in Toyama and other prefectures in Japan between late April 
and early May 2011. The course of the disease in some patients was extremely 
aggressive, and some cases were fatal [5]. Most of the severely affected HUS 
patients in this outbreak had neurological complications [5]. 
Tau protein is a microtubule-associated protein localized in both neurons and 
oligodendrocytes. It is found primarily in axons, at the branching points of cellular 
processes and at the ends of cellular extensions [7]. Tau protein is necessary for 
cytoskeletal structure and axonal transport [7]. Previous studies have reported that 
tau protein levels in the cerebrospinal fluid (CSF) and serum are elevated in patients 
with traumatic brain injury or CNS diseases, such as acute ischemic stroke [8-10] and 
acute encephalopathy (AE) [11]. Although little is known about the passage of tau 
from the brain into the blood, disruption of the blood brain barrier might lead to the 
leakage of tau from CSF to the blood.  
In this study, we examine serum tau protein levels in EHEC O111-induced HUS 
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(EHEC O111/HUS) to determine whether serum tau levels are useful to predict and 




Patients and methods 
 
Patients and samples 
 
An outbreak of EHEC O111 occurred in Toyama and other prefectures in Japan 
between late April and early May 2011. Serum and CSF samples were obtained from 
EHEC 0111-infected patients during the outbreak. Serum samples were obtained 
from 14 patients during the HUS phase, and CSF samples were also obtained from 2 
of these 14 patients (patient 2 and patient 7). Serum samples from 7 patients were 
obtained serially from the hemorrhagic colitis (HC) phase to the HUS phase. Serum 
samples from 3 patients were obtained in both the pre-HUS phase (1 day before the 
diagnosis of HUS) and the HUS phase.  
The clinical characteristics of the patients with EHEC O111/HUS are shown in 
Table 1. EHEC O111 infection was diagnosed based on the presence of bloody 
diarrhea, vomiting, and/or bowel cramps with microbiological identification of EHEC 
O111. HUS was defined by thrombocytopenia (platelet count of <150,000/mm3), 
hemolytic anemia, and acute renal dysfunction. Acute renal dysfunction was defined 
as renal injury evidenced by hematuria, proteinuria, or elevated creatinine levels (≥1.0 
mg/dl in children <13 years old and ≥1.5 mg/dl in patients ≥13 years old, or a ≥50% 
increase over baseline) [12]. AE was defined by the presence of behavioral 
abnormalities or neurological symptoms with pathological magnetic resonance 
imaging (MRI) findings.  
The severity of HUS was classified according to Gianantonio’s criteria: mild, no 
anuria; moderate, <7 days of anuria; and severe: ≥7 days of anuria [13]. One patient 
(patient 1) did not have anuria but suffered from AE, acute lung injury, and acute 
pancreatitis. Therefore, this patient was classified as severe. Eleven patients were 
classified as severe, no patients were classified as moderate, and three patients were 
classified as mild (Table 1). 
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Eight patients presented with complications of AE. Two patients died of AE with 
diffuse brain edema. Some patients developed neurological sequelae despite 
aggressive treatment, including continuous renal replacement therapy, plasma 
exchange, and anti-inflammatory therapy with steroids and intravenous 
immunoglobulin.  
Serum samples were also obtained from 20 patients with non-EHEC-related AE, 
including acute disseminated encephalomyelitis, biphasic seizures and late reduced 
diffusion, and AE associated with viral infections (such as influenza) and from 20 age- 
and sex-matched healthy controls. CSF samples were obtained from the same 20 
patients with non-EHEC-related AE. Serum and CSF samples were separated, 
divided into aliquots, frozen, and stored at −80°C until analysis. This study was 
approved by the institutional review board of Kanazawa University, and all patients 
provided informed consent for the collection and analysis of specimens. 
 
Quantification of tau protein and cytokines 
 
Serum concentrations of tau, neopterin, interleukin (IL)-6, tumor necrosis factor 
(TNF)-α, soluble TNF receptor (sTNFR)I, and sTNFRII were evaluated using 
commercial enzyme-linked immunosorbent assays, according to the manufacturer’s 
instructions (tau: Invitrogen, Camarillo, CA, USA; neopterin: IBL, Hamburg, Germany; 
IL-6, sTNFRI, and sTNFRII: R&D Systems, Inc., Minneapolis, MN, USA). CSF 
concentrations of tau were also evaluated using commercial enzyme-linked 
immunosorbent assays according to the manufacturer’s instructions (Invitrogen, 




Within-group comparisons were analyzed using the Mann–Whitney U test. 
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Correlations were expressed using the Spearman rank correlation coefficient. A 





Serum and CSF levels of tau protein in EHEC O111/HUS 
 
We determined serum levels of tau in patients with EHEC O111/HUS (with and 
without encephalopathy) and compared them with the levels in patients with 
non-EHEC-related AE and in healthy controls. Serum tau levels in patients with EHEC 
encephalopathy were significantly elevated compared with those in patients with 
EHEC 0111/HUS without encephalopathy, in patients with non-EHEC-related AE, and 
in healthy controls (Fig. 1A). Serum tau levels in patients with non-EHEC-related AE 
were significantly elevated compared with controls (Fig. 1A). CSF tau levels were 
determined in 2 patients with EHEC encephalopathy and 20 patients with 
non-EHEC-related AE. CSF tau levels were not elevated in two EHEC 
encephalopathy patients despite increased serum tau levels, whereas CSF tau levels 
were elevated in most of the patients with non-EHEC-related AE who had increased 
serum tau levels (Fig. 1B, C). The ratio of CSF tau levels to serum tau levels was >1.0 
in all patients with non-EHEC-related AE (Fig. 1C); however, it was <1.0 in the 2 
patients with EHEC encephalopathy (Fig. 1C). 
 
Changes in serum tau protein levels in patients with severe or mild EHEC O111/HUS 
 
To investigate whether serum tau protein levels reflect disease activity of EHEC 
O111/HUS, serum tau protein levels were serially monitored in 10 patients with EHEC 
O111/HUS (Fig. 2). Serum tau protein levels in patients with severe EHEC 0111/HUS 
who developed encephalopathy were rapidly and markedly elevated when HUS 
developed, whereas levels in patients with mild EHEC 0111/HUS were not elevated, 
even during the HUS phase. Furthermore, elevated serum tau protein levels in 2 
patients with severe EHEC 0111/HUS and encephalopathy were consistent with 
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abnormalities on brain MRI (Fig. 3). 
 
Correlation between serum tau protein and proinflammatory cytokine levels in 
patients with EHEC O111/HUS 
 
Serum tau protein levels were positively correlated with levels of the proinflammatory 






The presence of CNS dysfunction is an important predictive factor for morbidity and 
mortality in HUS [1]. In an outbreak of EHEC O104:H4 in Germany in May 2011, 30% 
of HUS patients showed signs and symptoms of encephalopathy, including delirium, 
stimulus-sensitive myoclonus, aphasia, and epileptic seizures requiring mechanical 
ventilation [14]. In the outbreak of EHEC O111 in Japan between late April and early 
May 2011 investigated in the present study, 169 people suffered from diarrhea, 30 
(17.8%) developed HUS, and encephalopathy developed in 14 (47%) of the HUS 
patients [5]. Furthermore, 5 hospitalized patients died from neurological 
manifestations, including somnolence, coma, and convulsions [5]. In view of the 
outcomes of this outbreak in Japan, we identified the need to establish a monitoring 
system with useful clinical markers to predict severe clinical outcomes, in particular 
AE, in patients with EHEC O111 infection. 
Tau is a microtubule stabilizing protein primarily localized in CNS neurons, but is 
also expressed at low levels in astrocytes and oligodendrocytes [15, 16]. Elevated 
levels of tau are seen in the CSF of patients with severe head injuries [8-10], AE [11], 
and neurodegenerative disease [17], suggesting its extracellular release during 
neuronal damage and supporting its role as a biomarker with specificity for brain injury. 
The potential movement of increased amounts of tau from the CSF across the blood–
brain barrier in brain disease or injury raises the possibility that measurements of 
serum tau could provide a convenient peripheral window into the status of the brain 
[18]. 
In the present study, we demonstrated that serum tau levels in patients with 
EHEC encephalopathy are significantly elevated compared with those in patients with 
EHEC 0111/HUS without encephalopathy. Serum tau levels in patients with severe 
EHEC 0111/HUS who developed encephalopathy were rapidly and markedly 
elevated at the start of the HUS phase, whereas levels in patients with mild EHEC 
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0111/HUS were not elevated, even during the HUS phase. Furthermore, changes in 
serum tau protein levels in patients with severe EHEC 0111/HUS and encephalopathy 
were consistent with abnormalities on brain MRI. These results indicate that serum 
tau protein levels might be a useful marker to reflect disease activity of EHEC 
O111/HUS. 
The pathophysiology of EHEC-associated HUS remains obscure. Endothelial 
cell damage is the main histopathological feature of HUS. Increasing experimental 
evidence suggests that immune responses of the host to Shiga toxin and/or 
lipopolysaccharide (LPS) are involved in the pathophysiology of EHEC infections 
[19-21]. In the present study, we found that serum tau protein levels were positively 
correlated with proinflammatory cytokines including neopterin, IL-6, sTNFRI, and 
sTNFRII. These results indicate that these proinflammatory cytokines might be 
closely associated with the pathogenesis of brain injury in EHEC-associated HUS. 
These cytokines are useful to predict neurological complications in patients with HUS, 
as we previously reported [3, 4]. Combined monitoring of serum tau and these 
proinflammatory cytokines might be useful in the clinical management of 
EHEC-associated HUS. 
Previous studies have shown that tau protein levels in CSF and serum are 
elevated in patients with various CNS diseases including AE [8-11, 17]. It is thought 
that increased levels of serum tau could be related to the leakage of tau from the CSF 
to the blood after disruption of the blood–brain barrier [18]. As shown in Fig. 1C, the 
ratio CSF tau levels to serum tau levels was >1.0 in all patients with 
non-EHEC-related AE. These results support this hypothesis.  
 However, in contrast to patients with non-EHEC-related AE, in 2 patients 
with EHEC encephalopathy, CSF tau levels were not elevated, despite elevated 
levels of serum tau. Therefore, the ratio of CSF tau level to serum tau level was <1.0 
(Fig. 1C). This serum dominant pattern for tau levels observed in EHEC 
encephalopathy was unique. Endothelial cell damage is the main pathological feature 
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of HUS. In rabbits, Shiga toxin passes through the blood–brain barrier promptly after 
intravenous injection, and localizes on the endothelial cells of capillaries, ependymal 
cells, and myelin sheaths in 24–57 h [22]. Because deterioration of the blood–brain 
barrier occurs in the early stage of HUS, tau protein released from injured axons 
might leak rapidly into the vascular space, resulting in a serum-dominant increase in 
tau protein in EHEC encephalopathy. 
 A limitation of the present study was the small number of patients with 
EHEC O111/HUS. A study with a larger sample including other serotypes of EHEC 
infection would help to determine the true diagnostic value of serum tau protein. 
Despite this limitation, our results indicate that serum tau protein might be useful to 
predict disease activity and severity of neurological complications in EHEC 
O111/HUS. 
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Table 1 Clinical characteristics of patients with Escherichia coli O111-induced 








Fig.1 Serum and cerebrospinal fluid (CSF) levels of tau protein 
(A) Serum levels of tau protein at the time of diagnosis of hemolytic uremic syndrome 
(HUS) in patients with Escherichia coli O111-induced HUS (EHEC O111/HUS) with 
and without encephalopathy, in patients with non-EHEC-related acute 
encephalopathy (AE), and in healthy controls. Bars represent the median values. 
Statistically significant differences between groups are p < 0.05.  
(B) CSF levels of tau protein at the time of diagnosis of HUS in 2 patients with severe 
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EHEC O111/HUS and AE and in patients with non-EHEC-related AE. Bars represent 
the median values.  
(C) Plot of the serum and CSF levels of tau protein during the HUS phase in 2 patients 





Fig. 2 Longitudinal changes of serum tau protein in patients with Escherichia coli 
O111-induced hemolytic uremic syndrome (EHEC O111/HUS)  
(A) Serum tau protein levels in patients with severe EHEC O111/HUS and 




Fig. 3 Longitudinal assessment of serum tau protein in 2 patients with Escherichia coli 
O111-induced hemolytic uremic syndrome 
 (A) case 2, (B) case 6. Changes in serum tau protein levels (solid lines) are shown in 
the upper panels and the details of the therapeutic interventions are shown in the 
lower panels.  
MRI magnetic resonance image, IVIG intravenous immunoglobulin, mPSL 









Fig. 4 Positive correlations between serum tau protein levels and proinflamamtory 
cytokines at the time of diagnosis of hemolytic uremic syndrome (HUS) in patients 
with Escherichia coli O111-induced HUS  
(A) neopterin, (B) IL-6, (C) TNF-α, (D) sTNFRI, and (E) sTNFRII.  
IL, interleukin; TNF, tumor necrosis factor; sTNFR, soluble TNF receptor 
 
 
